119 related articles for article (PubMed ID: 22244809)
1. Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteers.
Sturm S; Seiberling M; Weick I; Paehler A; Funk C; Ruf T
Clin Ther; 2012 Feb; 34(2):420-9. PubMed ID: 22244809
[TBL] [Abstract][Full Text] [Related]
2. No evidence of QT prolongation with supratherapeutic doses of aleglitazar.
Sturm S; Bentley D; Jordan P; Russell-Yarde F; Ruf T
J Cardiovasc Pharmacol; 2012 Mar; 59(3):288-97. PubMed ID: 22113345
[TBL] [Abstract][Full Text] [Related]
3. Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin.
Foley-Comer AJ; Young AM; Russell-Yarde F; Jordan P
Expert Opin Investig Drugs; 2011 Jan; 20(1):3-12. PubMed ID: 21114416
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study.
Sanwald-Ducray P; Liogier D'ardhuy X; Jamois C; Banken L
Clin Pharmacol Ther; 2010 Aug; 88(2):197-203. PubMed ID: 20336066
[TBL] [Abstract][Full Text] [Related]
5. Effects of high dose aleglitazar on renal function in patients with type 2 diabetes.
Herz M; Gaspari F; Perico N; Viberti G; Urbanowska T; Rabbia M; Wieczorek Kirk D
Int J Cardiol; 2011 Sep; 151(2):136-42. PubMed ID: 20837369
[TBL] [Abstract][Full Text] [Related]
6. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
[TBL] [Abstract][Full Text] [Related]
7. The effect of aleglitazar on the pharmacokinetics and pharmacodynamics of S- and R-warfarin in healthy male subjects.
Sanwald-Ducray P; Jamois C; Banken L
J Cardiovasc Pharmacol; 2014 Feb; 63(2):152-7. PubMed ID: 24157957
[TBL] [Abstract][Full Text] [Related]
8. Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection.
Wang L; Zhang D; Swaminathan A; Xue Y; Cheng PT; Wu S; Mosqueda-Garcia R; Aurang C; Everett DW; Humphreys WG
Drug Metab Dispos; 2006 Mar; 34(3):427-39. PubMed ID: 16381667
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Cavender MA; Lincoff AM
Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
[TBL] [Abstract][Full Text] [Related]
10. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
Henry RR; Lincoff AM; Mudaliar S; Rabbia M; Chognot C; Herz M
Lancet; 2009 Jul; 374(9684):126-35. PubMed ID: 19515415
[TBL] [Abstract][Full Text] [Related]
11. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers.
Bello CL; Smith E; Ruiz-Garcia A; Ni G; Alvey C; Loi CM
Cancer Chemother Pharmacol; 2013 Aug; 72(2):379-85. PubMed ID: 23760812
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers.
Blight AR; Henney HR
Clin Ther; 2009 Feb; 31(2):328-35. PubMed ID: 19302905
[TBL] [Abstract][Full Text] [Related]
13. Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia.
Chen Y; Chen H; Birnbaum Y; Nanhwan MK; Bajaj M; Ye Y; Qian J
Diab Vasc Dis Res; 2017 Mar; 14(2):152-162. PubMed ID: 28111985
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R
Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
[TBL] [Abstract][Full Text] [Related]
15. Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite.
Bopst M; Atzpodien EA
Regul Toxicol Pharmacol; 2017 Jun; 86():107-116. PubMed ID: 28274810
[TBL] [Abstract][Full Text] [Related]
16. Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.
Lecka-Czernik B
IDrugs; 2010 Nov; 13(11):793-801. PubMed ID: 21046527
[TBL] [Abstract][Full Text] [Related]
17. Structural elucidation of human oxidative metabolites of muraglitazar: use of microbial bioreactors in the biosynthesis of metabolite standards.
Zhang D; Zhang H; Aranibar N; Hanson R; Huang Y; Cheng PT; Wu S; Bonacorsi S; Zhu M; Swaminathan A; Humphreys WG
Drug Metab Dispos; 2006 Feb; 34(2):267-80. PubMed ID: 16280454
[TBL] [Abstract][Full Text] [Related]
18. Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.
Hansen BC; Tigno XT; Bénardeau A; Meyer M; Sebokova E; Mizrahi J
Cardiovasc Diabetol; 2011 Jan; 10():7. PubMed ID: 21251281
[TBL] [Abstract][Full Text] [Related]
19. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-γ agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects.
Kim JW; Kim JR; Yi S; Shin KH; Shin HS; Yoon SH; Cho JY; Kim DH; Shin SG; Jang IJ; Yu KS
Clin Ther; 2011 Nov; 33(11):1819-30. PubMed ID: 22047812
[TBL] [Abstract][Full Text] [Related]
20. Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial.
Koomen JV; Heerspink HJL; Schrieks IC; Schwartz GG; Lincoff AM; Nicholls SJ; Svensson A; Wedel H; Weichert A; Grobbee DE; Stevens J
Diabetes Obes Metab; 2020 Jan; 22(1):30-38. PubMed ID: 31468659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
